CGT6297

Phase 1Small molecule

CCogent Biosciences, Inc.

CGT6297 is one of 3 small molecule programs targeting PIK3CA Mutation. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PIK3CA MutationRecruiting

PIK3CA MutationPhase 1

Recruiting

Competition

Competitive Landscape

3 competitors in PIK3CA Mutation

#DrugCompanyPhaseTrials

Faslodex

FFresenius Kabi USA, LLC

Phase 3

1 2

Copanlisib Hydrochloride

NNational Cancer Institute (NCI)

Phase 2

1 3

CGT6297

CCogent Biosciences, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 1Recruiting

PIK3CA Mutation

NCT07383506

Clinical

Trials by Indication[1]

PIK3CA Mutation1 trial

A Study of a Mutant-Selective Inhibitor, CGT6297, in Patients With Advanced Solid Tumors Harboring PIK3CA Mutations

Recruiting·CCogent Biosciences, Inc.·Phase 1·NCT07383506·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CGT6297. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CGT6297 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CGT6297. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cogent Biosciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCogent Biosciences, Inc.

CGT6297

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

PIK3CA Mutation1 trial

References

Drug Info

Quick Facts

Related News